RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $46.54 million. The enterprise value is $35.04 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, before market open.
Earnings Date | Nov 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 36.65 million shares outstanding. The number of shares has increased by 95.52% in one year.
Current Share Class | 36.65M |
Shares Outstanding | 36.65M |
Shares Change (YoY) | +95.52% |
Shares Change (QoQ) | +16.50% |
Owned by Insiders (%) | 3.34% |
Owned by Institutions (%) | 9.61% |
Float | 30.08M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 57.08 |
Forward PS | 17.21 |
PB Ratio | 4.41 |
P/TBV Ratio | 4.43 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 52.92 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.02.
Current Ratio | 8.61 |
Quick Ratio | 8.15 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -107.11% and return on invested capital (ROIC) is -69.70%.
Return on Equity (ROE) | -107.11% |
Return on Assets (ROA) | -54.82% |
Return on Invested Capital (ROIC) | -69.70% |
Return on Capital Employed (ROCE) | -93.06% |
Revenue Per Employee | $66,200 |
Profits Per Employee | -$1.07M |
Employee Count | 10 |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.79% in the last 52 weeks. The beta is 1.23, so RenovoRx's price volatility has been higher than the market average.
Beta (5Y) | 1.23 |
52-Week Price Change | +8.79% |
50-Day Moving Average | 1.17 |
200-Day Moving Average | 1.18 |
Relative Strength Index (RSI) | 56.75 |
Average Volume (20 Days) | 579,524 |
Short Selling Information
The latest short interest is 198,095, so 0.54% of the outstanding shares have been sold short.
Short Interest | 198,095 |
Short Previous Month | 134,441 |
Short % of Shares Out | 0.54% |
Short % of Float | 0.66% |
Short Ratio (days to cover) | 0.91 |
Income Statement
In the last 12 months, RenovoRx had revenue of $662,000 and -$10.66 million in losses. Loss per share was -$0.36.
Revenue | 662,000 |
Gross Profit | 416,000 |
Operating Income | -11.25M |
Pretax Income | -8.05M |
Net Income | -10.66M |
EBITDA | n/a |
EBIT | -11.25M |
Loss Per Share | -$0.36 |
Full Income Statement Balance Sheet
The company has $12.31 million in cash and $260,000 in debt, giving a net cash position of $12.05 million or $0.33 per share.
Cash & Cash Equivalents | 12.31M |
Total Debt | 260,000 |
Net Cash | 12.05M |
Net Cash Per Share | $0.33 |
Equity (Book Value) | 10.64M |
Book Value Per Share | 0.29 |
Working Capital | 11.84M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$10.31 million and capital expenditures -$14,000, giving a free cash flow of -$10.32 million.
Operating Cash Flow | -10.31M |
Capital Expenditures | -14,000 |
Free Cash Flow | -10.32M |
FCF Per Share | -$0.28 |
Full Cash Flow Statement Margins
Gross Margin | 62.84% |
Operating Margin | -1,699.09% |
Pretax Margin | -1,610.88% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -95.52% |
Shareholder Yield | -95.52% |
Earnings Yield | -22.65% |
FCF Yield | -21.92% |
Analyst Forecast
The average price target for RenovoRx is $7.50, which is 490.55% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $7.50 |
Price Target Difference | 490.55% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 394.31% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RenovoRx has an Altman Z-Score of -0.83 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.83 |
Piotroski F-Score | 1 |